Nmes1 Antibody

What is Nmes1 and what physiological processes is it involved in?

Nmes1 (Normal Mucosa of Esophagus-Specific gene 1), also known as C15ORF48, is a gene encoding a small protein of 83 amino acids that functions as a novel regulator of mucosal response and intestinal healing. Current research indicates that Nmes1 plays significant roles in multiple physiological processes:

• Regulation of intestinal inflammation in type 2-dominated environments

• Influence on macrophage response to tissue remodeling cytokines (particularly IL-4)

• Modulation of intestinal regeneration during recovery from colitis

• Impact on parasitic egg clearance and fibrosis reduction during advanced stages of infection

• Interactions with CX3CR1+ macrophages, which have wound-healing potential in inflamed colon

Additionally, Nmes1 has been identified as a stress-independent inducer of autophagy, regulating oxidative stress and potentially contributing to self-tolerance mechanisms . Research suggests it may function as a tumor suppressor gene, particularly expressed in epithelial tissues .

What are the primary applications for Nmes1 antibodies in research settings?

Nmes1 antibodies serve several critical research applications:

Researchers have successfully applied these techniques in various tissue types, including human testis tissue, mouse colon tissue, and mouse testis tissue . When studying inflammatory processes or autophagy pathways, Nmes1 antibodies provide valuable insights into regulatory mechanisms involving this protein.

How should researchers validate the specificity of Nmes1 antibodies?

Validation of Nmes1 antibody specificity is crucial for reliable experimental outcomes. A methodological approach should include:

• Positive and negative controls: Use tissues known to express Nmes1 (like epithelial tissues) as positive controls. For negative controls, utilize Nmes1-deficient (C15orf48−/−) samples when available, as mentioned in research where "the mean fluorescent intensity (MFI) for antibody binding in wild-type TECs was subtracted from that in TECs from C15orf48-deficient (C15orf48–/–) mice" .

• Knockdown validation: Perform siRNA-mediated knockdown of C15ORF48 using validated siRNAs (such as s38981 and s228367) as described in literature , then confirm reduced antibody signal.

• Cross-reactivity assessment: Evaluate potential cross-reactivity with related proteins, particularly NDUFA4 and NDUFA4L2, which have been studied in conjunction with C15ORF48 .

• Western blot analysis: Confirm that the detected protein corresponds to the expected molecular weight of Nmes1 (approximately 9-10 kDa as observed in experimental conditions) .

• Multiple antibody comparison: When possible, compare results using different antibodies targeting distinct epitopes of Nmes1.

How can researchers optimize Nmes1 antibody-based protocols for detecting low-abundance expression in inflammatory conditions?

Detecting low-abundance Nmes1 expression, particularly in inflammatory conditions, requires optimization strategies:

• Signal amplification techniques:

  • Implement tyramide signal amplification (TSA) for immunohistochemistry

  • Use high-sensitivity ECL substrates for Western blotting

  • Consider biotin-streptavidin amplification systems similar to those used in the NMES1 ELISA kit

• Sample enrichment:

  • Perform subcellular fractionation to concentrate mitochondrial components where C15ORF48 localizes

  • Isolate specific cell populations (e.g., CX3CR1+ macrophages) using FACS or magnetic separation

  • Implement immunoprecipitation prior to detection

• Reducing background interference:

  • Optimize blocking procedures with appropriate blockers (BSA, normal serum)

  • Extend washing steps and increase detergent concentration

  • Use sample-specific validated antibody dilutions (typically ranging from 1:2000-1:10000 for Western blotting)

• Inflammatory model considerations:

  • Time course experiments to capture peak expression windows

  • Compare Nmes1 levels across different inflammatory models (e.g., IL-1α stimulation vs. TNF exposure)

  • Consider the differential expression patterns observed in type 2-dominated inflammatory environments

• Validation with complementary techniques:

  • Correlate protein detection with RT-qPCR analysis of Nmes1 transcript levels

  • Combine with functional assays measuring autophagy or oxidative stress parameters

What are the key considerations when designing experiments to investigate Nmes1's role in autophagy using specific antibodies?

When investigating Nmes1's role in autophagy pathways, researchers should consider:

• Experimental design framework:

  • Include appropriate controls for autophagy (e.g., starvation-induced, rapamycin-treated)

  • Design time-course experiments to capture the dynamic nature of autophagy

  • Compare C15ORF48 expression and autophagy markers simultaneously

• Antibody selection and validation:

  • Use anti-C15orf48/NMES1 antibodies validated for autophagy research contexts

  • Combine with established autophagy markers (e.g., LC3, as mentioned in research using "anti-LC3 (PM036; MBL)" )

  • Include mitochondrial markers (e.g., "anti-TOM20 (42406; Cell)" ) to assess organelle-specific effects

• Genetic manipulation approaches:

  • Implement siRNA knockdown of C15ORF48 using validated sequences (s38981, s228367)

  • Consider parallel knockdown of autophagy machinery components (ATG5, ATG7) to demonstrate pathway dependence

  • Establish stable cell pools expressing C15ORF48 for gain-of-function studies

• Signaling pathway analysis:

  • Investigate AMPK-ULK1 signaling, as research indicates "inflammatory stimuli induce expression of C15ORF48 to promotes stress-independent autophagy via AMPK-ULK1 signaling"

  • Monitor mTOR pathway components

  • Assess oxidative stress parameters and glutathione levels, as C15ORF48 has been shown to "promote cell survival by eliminating oxidative stress via upregulation of glutathione levels"

• Cell type considerations:

  • Compare results between cell types with differing basal autophagy levels (e.g., MDA-MB-231 vs. A549 cells)

  • Consider the impact of NF-κB activation status on C15ORF48 expression and autophagy induction

How can researchers distinguish between Nmes1's direct effects and secondary consequences when studying inflammatory processes?

Distinguishing direct effects from secondary consequences requires sophisticated experimental approaches:

• Temporal analysis strategies:

  • Implement precise time-course experiments with early time points (minutes to hours)

  • Use inducible expression systems to control Nmes1 expression timing

  • Compare kinetics of Nmes1 expression with downstream inflammatory markers

• Pathway inhibition approaches:

  • Selectively inhibit known inflammatory signaling (e.g., using IKK inhibitor SC-514 as described in literature)

  • Compare effects of Nmes1 knockdown with targeted pathway inhibition

  • Implement rescue experiments with recombinant Nmes1 protein

• Direct interaction studies:

  • Perform co-immunoprecipitation with Nmes1 antibodies to identify binding partners

  • Use proximity ligation assays to confirm protein-protein interactions in situ

  • Implement CRISPR-based tagging of endogenous Nmes1 for live-cell imaging

• Genetic dissection approaches:

  • Create domain-specific mutants to map functional regions of Nmes1

  • Employ cell-specific conditional knockout models

  • Compare inflammatory phenotypes between complete knockout and cell-specific deletion

• Multi-omics integration:

  • Correlate proteomics, transcriptomics, and metabolomics data to trace direct vs. cascade effects

  • Implement computational network analysis to predict direct vs. indirect targets

  • Compare datasets from acute vs. chronic inflammatory models

How should researchers approach Nmes1 antibody selection for studies in intestinal inflammation models?

When selecting Nmes1 antibodies for intestinal inflammation studies, consider:

• Model-specific antibody validation:

  • Validate antibody performance specifically in intestinal tissues

  • Confirm specificity in both healthy and inflamed intestinal samples

  • Test antibody performance in multiple intestinal inflammation models described in literature, including "two models of intestinal inflammation, each characterized by a type 2-dominated environment with contrasting functions"

• Epitope considerations:

  • Select antibodies targeting conserved regions when comparing across species

  • Consider N-terminal targeting antibodies like ABIN2784037 for detection of full-length protein

  • Evaluate epitope accessibility in fixed vs. frozen tissues

• Application-specific selection:

  • For mechanistic studies examining Nmes1's role in "mucosal healing" , select antibodies validated in both protein detection and functional assays

  • For co-localization with macrophage markers (particularly CX3CR1+ macrophages), choose antibodies compatible with multi-color immunofluorescence

  • For quantitative analysis, consider antibodies validated for ELISA applications

• Experimental controls:

  • Include tissues from C15orf48-deficient models as negative controls

  • Use recombinant Nmes1 protein for antibody validation

  • Compare antibody performance across different vendors when possible

• Consideration of post-translational modifications:

  • Select antibodies that detect Nmes1 regardless of inflammatory-induced modifications

  • When studying regulation, consider using modification-specific antibodies if available

What are the methodological challenges in studying Nmes1's role in macrophage-mediated tissue repair using antibody-based approaches?

Studying Nmes1's role in macrophage-mediated tissue repair presents several methodological challenges:

• Macrophage heterogeneity issues:

  • Distinguish between different macrophage populations, particularly focusing on "CX3CR1+ macrophages, cells known for their wound-healing potential in the inflamed colon"

  • Implement multi-parameter flow cytometry with Nmes1 antibodies

  • Consider single-cell approaches to account for macrophage subpopulation heterogeneity

• Technical limitations in tissue analysis:

  • Optimize tissue processing to preserve both macrophage morphology and Nmes1 antigenicity

  • Implement clearing techniques for thick tissue sections to allow 3D visualization

  • Develop strategies to distinguish resident vs. infiltrating macrophages in repair contexts

• Dynamic process tracking:

  • Design temporal sampling to capture all phases of the wound healing response

  • Implement lineage tracing combined with Nmes1 antibody staining

  • Develop ex vivo systems that allow real-time imaging of macrophage behavior

• Functional correlation challenges:

  • Correlate Nmes1 expression with specific macrophage functions in the wound healing process

  • Develop assays that link antibody-detected expression levels with quantitative healing metrics

  • Implement macrophage-specific Nmes1 manipulation combined with wound healing assessment

• Confounding factors:

  • Control for the influence of the microbiome on intestinal macrophage function

  • Account for the impact of "type 2-dominated environment" on experimental interpretation

  • Distinguish effects of Nmes1 on macrophages from effects on intestinal epithelial cells

How can researchers effectively use Nmes1 antibodies to study its role in autophagy-mediated stress responses?

To effectively study Nmes1's role in autophagy-mediated stress responses:

• Integrated detection approaches:

  • Combine Nmes1 antibody detection with established autophagy markers (LC3-I/II conversion, p62)

  • Implement co-localization studies of Nmes1 with autophagosome markers

  • Correlate Nmes1 expression with mitochondrial markers, given its role as a "mitochondrial protein"

• Stress condition optimization:

  • Compare inflammatory stress (IL-1α, TNF) with other stress forms (oxidative, ER stress)

  • Implement dose-response and time-course analyses to capture the dynamics of Nmes1 induction

  • Control for stress-independent autophagy induction, as C15ORF48 is described as a "stress-independent inducer of autophagy"

• Pathway delineation strategies:

  • Use specific inhibitors of autophagy (e.g., ULK1 inhibitors mentioned in literature)

  • Implement siRNA knockdown of autophagy components (ATG5, ATG7) as described in studies

  • Monitor AMPK-ULK1 signaling components with phospho-specific antibodies

• Functional outcome assessment:

  • Measure glutathione synthesis changes, as research shows "C15ORF48-dependent autophagy promotes glutathione synthesis"

  • Assess oxidative stress resistance using appropriate stress inducers

  • Evaluate cell viability in response to oxidative challenges after modulating Nmes1 levels

• Model system considerations:

  • Compare results between cell types with different basal autophagy levels (e.g., MDA-MB-231 vs. A549)

  • Consider the impact of endogenous NF-κB activation status on experimental interpretation

  • Validate key findings across multiple cell types and primary cells when possible

What are common troubleshooting approaches for inconsistent Nmes1 detection in Western blotting?

When encountering inconsistent Nmes1 detection in Western blotting, consider:

• Sample preparation optimization:

  • Ensure complete protein denaturation and solubilization

  • Test different lysis buffers (the literature mentions "TNE buffer (10 mM Tris-HCl, 150 mM NaCl, 10 mM Triton X-100, and cOmplete (Sigma-Aldrich); pH 7.4)" )

  • Include protease inhibitors to prevent degradation of the small (9-10 kDa) Nmes1 protein

  • Consider sonication steps as described in protocols: "Homogenized tissues were sonicated and then centrifuged at 10,000 × g for 5 min at 4 °C"

• Transfer and detection adjustments:

  • Optimize transfer conditions for small proteins (use PVDF membranes with appropriate pore size)

  • Adjust methanol concentration in transfer buffer

  • Consider semi-dry transfer for small proteins like Nmes1

  • Test multiple antibody dilutions within the recommended range (1:2000-1:10000)

• Blocking and washing optimization:

  • Test different blocking agents (BSA vs. non-fat dry milk)

  • Adjust blocking time and temperature

  • Increase washing stringency to reduce background

  • Consider using specialized blocking reagents for problematic samples

• Gel percentage considerations:

  • Use higher percentage gels (15-20%) to better resolve the small Nmes1 protein

  • Consider gradient gels for experiments comparing Nmes1 with larger proteins

  • Adjust running conditions (voltage/time) for optimal separation

• Control experiments:

  • Include positive controls (human testis tissue, mouse colon tissue, mouse testis tissue)

  • Implement loading controls appropriate for small proteins

  • Consider parallel detection with multiple Nmes1 antibodies targeting different epitopes

How should researchers address potential cross-reactivity concerns with Nmes1 antibodies?

To address potential cross-reactivity concerns:

• Comprehensive validation strategy:

  • Test antibody specificity in tissues/cells with Nmes1 knockout or knockdown

  • Perform peptide competition assays with the immunizing peptide

  • Evaluate cross-reactivity with structurally related proteins, particularly NDUFA4 protein, which research indicates "is regulated by miR-147b encoded in the 3′-" region

• Specificity confirmation approaches:

  • Compare staining patterns using multiple antibodies targeting different Nmes1 epitopes

  • Correlate protein detection with mRNA expression data

  • Perform immunodepletion experiments to confirm specificity

• Technical considerations for reducing non-specific binding:

  • Optimize antibody concentration based on signal-to-noise ratio

  • Increase washing stringency (duration, detergent concentration)

  • Pre-adsorb antibodies against tissues from knockout animals when available

  • Consider the observation from research that some antibodies show "relatively high non-specific binding... in flow cytometric analysis"

• Species-specific considerations:

  • Verify species cross-reactivity experimentally rather than relying solely on predicted reactivity

  • Be aware of the predicted reactivity profile: "Cow: 79%, Dog: 79%, Guinea Pig: 93%, Horse: 79%, Human: 100%, Mouse: 93%, Rabbit: 86%, Rat: 93%, Zebrafish: 79%"

  • When working across species, select antibodies targeting highly conserved epitopes

• Application-specific validation:

  • Validate specificity separately for each application (WB, IHC, IP, ELISA)

  • Consider that antibodies showing specificity in one application may not perform equally in others

  • Document and report all validation steps in publications

What strategies can researchers employ when Nmes1 antibodies show inconsistent results across different tissue types?

When encountering tissue-specific inconsistencies:

• Tissue processing optimization:

  • Compare different fixation methods for immunohistochemistry applications

  • Evaluate fresh vs. frozen vs. fixed tissues for protein preservation

  • Optimize extraction protocols specifically for each tissue type

• Expression level considerations:

  • Adjust detection methods based on known tissue-specific expression patterns

  • Implement more sensitive detection for tissues with lower expression levels

  • Consider the natural variation in Nmes1 expression across tissues (particularly high in "epithelial tissue" )

• Interfering factors identification:

  • Test for tissue-specific post-translational modifications affecting epitope recognition

  • Identify potential tissue-specific interfering proteins

  • Evaluate tissue-specific autofluorescence or endogenous peroxidase activity

• Positive control implementation:

  • Include known positive tissues (human testis tissue, mouse colon tissue) in each experiment

  • Use recombinant Nmes1 protein as a standard reference

  • Consider tissue spike-in experiments to assess matrix effects

• Protocol customization:

  • Develop tissue-specific protocols rather than using a one-size-fits-all approach

  • Adjust antibody concentration, incubation time, and temperature for each tissue type

  • Document optimal conditions for each tissue to ensure reproducibility

How should researchers interpret conflicting results between Nmes1 expression and functional outcomes in inflammation studies?

When faced with conflicts between Nmes1 expression and functional outcomes:

• Context-dependent function analysis:

  • Consider that Nmes1 may have different functions depending on the inflammatory context

  • Note the research showing that "the ablation of Nmes1 results in decreased intestinal regeneration during the recovery phase of colitis, while enhancing parasitic egg clearance and reducing fibrosis during the advanced stages of Schistosoma mansoni infection"

  • Evaluate the possibility of biphasic or time-dependent effects

• Cell-type specific effects assessment:

  • Analyze Nmes1 function in specific cell populations versus whole tissue

  • Consider differential effects on epithelial cells versus immune cells

  • Pay particular attention to "CX3CR1+ macrophages, cells known for their wound-healing potential"

• Pathway interaction evaluation:

  • Investigate potential compensatory mechanisms activated in response to Nmes1 modulation

  • Consider interaction with other inflammatory regulators

  • Examine cross-talk between inflammation and autophagy pathways

• Quantitative threshold considerations:

  • Determine if Nmes1 effects are dependent on expression level thresholds

  • Correlate expression levels quantitatively with functional outcomes

  • Consider non-linear relationships between expression and function

• Model-specific interpretation:

  • Compare results across different inflammatory models

  • Distinguish between acute and chronic inflammation scenarios

  • Consider species-specific differences when interpreting results

What considerations are important when quantifying Nmes1 levels using antibody-based techniques?

For accurate quantification of Nmes1 levels:

• Standardization approaches:

  • Develop standard curves using recombinant Nmes1 protein

  • Implement absolute quantification when possible using ELISA techniques

  • Consider the detection range of commercially available ELISA kits: "0.156 to 10 ng/ml" with a "sensitivity: 0.094 ng/ml"

• Technical considerations for accurate quantification:

  • Ensure measurements fall within the linear range of detection

  • Implement technical replicates to assess assay variability

  • Be aware of assay precision parameters: "Intra assay: CV <8%, Inter assay: CV <10%"

• Normalization strategies:

  • Carefully select appropriate housekeeping genes/proteins for normalization

  • Consider multiple normalization approaches for confirmation

  • Implement total protein normalization for Western blotting as an alternative to single protein references

• Sample-specific considerations:

  • Optimize protocols for each sample type (serum, plasma, tissue homogenates)

  • Be aware that different biological fluids may require specific sample preparation

  • Consider potential matrix effects in complex biological samples

• Dynamic range challenges:

  • Implement sample dilution strategies for high-expressing samples

  • Consider signal amplification for low-expressing samples

  • Validate quantification across the entire biological range of expression

How can researchers accurately distinguish between total and active forms of Nmes1 using antibody-based detection methods?

Distinguishing between total and active Nmes1 forms requires:

• Antibody selection strategies:

  • Use antibodies recognizing specific post-translational modifications associated with activation

  • Employ antibodies targeting conformation-specific epitopes if available

  • Consider developing phospho-specific antibodies if phosphorylation regulates Nmes1 activity

• Fractionation approaches:

  • Implement subcellular fractionation to isolate active pools (e.g., mitochondrial fractions)

  • Separate soluble versus membrane-associated forms

  • Consider native versus denatured protein analysis

• Functional correlation methods:

  • Correlate antibody-detected forms with functional readouts

  • Implement activity-based protein profiling when possible

  • Correlate with downstream effectors of Nmes1 activity

• Comparative analysis techniques:

  • Use multiple antibodies recognizing different epitopes/forms

  • Compare results across different detection platforms

  • Correlate with functional assays measuring autophagy or inflammatory responses

• Modification-specific detection:

  • Implement immunoprecipitation followed by modification-specific Western blotting

  • Consider mass spectrometry approaches to identify specific modifications

  • Develop assays that can capture the dynamic regulation of Nmes1 activity